Refractory vasoplegia remains a challenging complication following cardiopulmonary bypass (CPB), characterized by profound vasodilation, high vasopressor requirements, and hemodynamic instability despite adequate cardiac output. In this 2026 study published in the Journal of Cardiothoracic and Vascular Anesthesia, Teletnick et al. evaluated the impact of implementing a standardized, stepwise vasoplegia management protocol in patients undergoing cardiothoracic surgery with CPB .
Background
Vasoplegic syndrome after CPB is a form of distributive shock often associated with prolonged bypass time, reduced left ventricular function, preoperative renin-angiotensin-aldosterone system inhibitor use, and complex surgical procedures. When conventional catecholamine vasopressors fail, clinicians frequently turn to non-catecholamine rescue agents such as methylene blue, hydroxocobalamin, and angiotensin II. However, no standardized algorithm has existed to guide their optimal sequencing or timing.
The authors hypothesized that a structured escalation protocol could improve hemodynamic efficiency and reduce costs without compromising patient outcomes.
Study Design
This was a single-center, observational pre-post cohort study conducted at a high-volume academic cardiothoracic surgery center. A total of 215 adult patients undergoing CPB who required at least one intraoperative rescue agent for refractory vasoplegia were included:
- Pre-protocol group (n = 119): Rescue therapy administered at provider discretion
- Post-protocol group (n = 96): Managed using a standardized stepwise protocol
Refractory vasoplegia was defined as requiring ≥0.25 µg/kg/min norepinephrine equivalents (NEeq) with inability to maintain mean arterial pressure (MAP) ≥65 mmHg (page 2–3).
The Standardized Protocol
Implemented January 1, 2024, the stepwise approach included:
- Methylene Blue (1–2 mg/kg IV bolus)
- Angiotensin II infusion (10 ng/kg/min, titrated)
- Hydroxocobalamin (5 g IV over 15 minutes)
Escalation occurred intraoperatively if MAP targets were not maintained. The protocol emphasized early rescue at the defined NEeq threshold.
According to Table 2 (page 5), methylene blue was used in 94% of post-protocol patients, while angiotensin II was administered in 31%, and hydroxocobalamin in only 9%. In contrast, the pre-protocol group primarily received hydroxocobalamin (94%).
Primary Effectiveness Outcome
The primary clinical endpoint was the percentage change in norepinephrine equivalents (%ΔNEeq) over the first 3 hours after rescue initiation.
As shown in Table 3 and Figure 2 (page 5), implementation of the protocol resulted in:
- An additional 2.01% NEeq reduction per 15-minute interval compared to pre-protocol management (p < 0.01)
- More than double the rate of vasopressor decline relative to prior practice
For example, over the first 2 hours:
- Pre-protocol: 9.8% reduction in NEeq
- Post-protocol: 23.7% reduction in NEeq
Importantly, mean arterial pressure (MAP) trajectories were similar between groups, indicating that faster vasopressor weaning did not compromise hemodynamic stability.
A sensitivity analysis demonstrated that when angiotensin II recipients were excluded, the effect size attenuated and lost statistical significance. This suggests that timely escalation to angiotensin II may account for a substantial portion of the protocol’s benefit.
Primary Cost Outcome
Cost analysis used Federal Supply Schedule pricing. The primary cost endpoint was total vasopressor expenditure within 48 hours.
From Table 4 (page 6):
- Cost ratio = 0.74 (95% CI 0.65–0.85)
- Represents a 26% reduction in vasopressor costs at 48 hours
- Mean savings: $365 per patient
Unadjusted costs fell from $1,409 to $1,037 at 48 hours (Table 2).
Extrapolated to 100 surgical procedures, this equates to approximately $36,500 in cost savings, a significant economic impact for large cardiothoracic centers.
Secondary Outcomes
No statistically significant differences were observed in:
- 30-day mortality
- Acute kidney injury
- Tachyarrhythmia
- ICU length of stay
- Time to vasopressor discontinuation
- Postoperative lactate levels
These findings suggest that accelerated vasopressor reduction did not adversely affect short-term clinical outcomes.
Mechanistic Interpretation
The authors propose that the protocol’s effectiveness may derive from:
- Earlier rescue therapy initiation
- Mechanistic diversity in vasoconstrictor pathways
- Strategic use of angiotensin II targeting renin-angiotensin-aldosterone system activation
Under vasoplegic conditions, endogenous angiotensin II production may be insufficient due to ACE pathway saturation. Early angiotensin II administration may restore vascular tone through a distinct pathway compared to nitric oxide–mediated agents like methylene blue and hydroxocobalamin.
The reduced rebound in vasopressor requirement around 75 minutes (Figure 2) supports the benefit of structured escalation.
Subgroup Analyses
- STS Index Surgeries (n = 93): Significant 48-hour cost reduction ($456 savings per patient)
- Transplant/VAD subgroup (n = 36): Trends toward improved NEeq reduction and lower costs, but underpowered for statistical significance
Limitations
- Single-center design limits generalizability
- Observational pre-post design susceptible to secular trends
- Subgroup analyses underpowered
- Cost analysis did not include downstream length-of-stay savings
Despite these limitations, baseline characteristics were largely balanced, and robust statistical modeling was used.
Clinical Implications
This study demonstrates that a standardized protocol for refractory vasoplegia management after CPB can:
- Accelerate vasopressor weaning
- Maintain hemodynamic stability
- Significantly reduce vasopressor costs
The findings support earlier and structured use of non-catecholamine agents—particularly angiotensin II—within a defined algorithm.
Future multi-center prospective trials are warranted to validate these findings and assess long-term outcomes.
